Wistar Institute

Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.

Itus is using artificial intelligence and flow-cytometry analysis of immune cells from an individual's blood to identify patients with tumors. 

The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.